Ayala Pharmaceuticals, Inc.
ADXS · OTC
12/31/2023 | 12/31/2022 | 10/31/2022 | 1/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | – | $0 |
| - Cash | $0 | $0 | – | $0 |
| + Debt | $0 | $0 | – | $0 |
| Enterprise Value | $0 | -$0 | – | -$0 |
| Revenue | $0 | $0 | – | – |
| % Growth | -94.8% | – | – | – |
| Gross Profit | $0 | -$0 | – | – |
| % Margin | 0% | -25.6% | – | – |
| EBITDA | -$0 | -$0 | – | – |
| % Margin | -275,915.4% | -6,310.4% | – | – |
| Net Income | -$0 | -$0 | – | – |
| % Margin | -369,784.6% | -5,743.6% | – | – |
| EPS Diluted | -7.99 | -7.9 | – | – |
| % Growth | -1.1% | – | – | – |
| Operating Cash Flow | -$0 | – | -$0 | – |
| Capital Expenditures | $0 | – | -$0 | – |
| Free Cash Flow | -$0 | – | -$0 | – |